Prospective comparison of transthoracic versus transhiatal esophagectomy following neoadjuvant therapy for esophageal cancer

2007 ◽  
Vol 20 (3) ◽  
pp. 225-231 ◽  
Author(s):  
M. A. Morgan ◽  
W. G. Lewis ◽  
A. N. Hopper ◽  
X. Escofet ◽  
T. J. Havard ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Neoadjuvant Therapy ◽  
Transhiatal Esophagectomy ◽  
Prospective Comparison

Self-Expanding Metal Stents Improve Swallowing and Maintain Nutrition During Neoadjuvant Therapy for Esophageal Cancer

2017 ◽  
Vol 62 (6) ◽  
pp. 1647-1656 ◽  
Author(s):  
Zachary L. Smith ◽  
Jason E. Gonzaga ◽  
George B. Haasler ◽  
Elizabeth M. Gore ◽  
Kulwinder S. Dua
Keyword(s):  
Esophageal Cancer ◽  
Neoadjuvant Therapy ◽  
Metal Stents ◽  
Self Expanding Metal Stents

Modern Staging and Utility of PET Imaging in Esophageal Cancer Management

2008 ◽  
Vol 6 (9) ◽  
pp. 862-869 ◽  
Author(s):  
Kwang-Yu Chang ◽  
Jang-Yang Chang ◽  
Joseph Chao ◽  
Yun Yen
Keyword(s):  
Esophageal Cancer ◽  
Neoadjuvant Therapy ◽  
Imaging System ◽  
False Negative ◽  
Lymph Node Involvement ◽  
Cancer Management ◽  
Positron Emission ◽  
Node Involvement ◽  
Positive Results ◽  
Locoregional Lymph Node

Esophageal cancer is the eighth most common cancer worldwide, and one of the most fatal diseases despite modern medical treatment. Because correct staging and surveillance of neoadjuvant therapy for esophageal cancer is mandatory for further treatment planning, choosing a modern imaging system is important. The development of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) has provided alternate means of tumor detection distinct from more conventional methods. This modality has extraordinary performance in detecting locoregional lymph node involvement and distant metastatic disease, and has been introduced as a powerful tool in many guidelines. However, some factors still lead to false-negative or -positive results, raising questions of its accuracy. This article discusses the clinical efficacy of PET in staging and surveillance of neoadjuvant therapy in esophageal cancer, comparing its accuracy with conventional imaging modalities.

Effects of an immuno-enhanced diet containing antioxidants in esophageal cancer surgery following neoadjuvant therapy

2011 ◽  
Vol 25 (2) ◽  
pp. 137-145 ◽  
Author(s):  
S. Aiko ◽  
I. Kumano ◽  
N. Yamanaka ◽  
H. Tsujimoto ◽  
R. Takahata ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Neoadjuvant Therapy ◽  
Cancer Surgery ◽  
Esophageal Cancer Surgery

scholarly journals Neoadjuvant therapy for esophageal cancer: Who, when, and what?

Cancer ◽  
2018 ◽  
Vol 124 (22) ◽  
pp. 4276-4278 ◽  
Author(s):  
Megan Greally ◽  
David H. Ilson
Keyword(s):  
Esophageal Cancer ◽  
Neoadjuvant Therapy

scholarly journals Comparison of Short-term Outcome of Thoracoscopic-Laparoscopic Esophagectomy Versus Transhiatal Esophagectomy for Resectable Esophageal Cancer

2021 ◽  
Vol 11 (1) ◽  
pp. 31113.1-31113.6
Author(s):  
Touraj Asvadi Kermani ◽  
◽  
Seyed Ziaeddin Rasihashemi ◽  
Hoseinpour Feyzi ◽  
Moein Hoseinpour Feyzi ◽  
...  
Keyword(s):  
Overall Survival ◽  
Esophageal Cancer ◽  
Blood Loss ◽  
Similar Rate ◽  
Transhiatal Esophagectomy ◽  
Term Outcome ◽  
Laparoscopic Esophagectomy ◽  
Resectable Esophageal ◽  
Resectable Esophageal Cancer ◽  
One Year

Background: Esophagectomy is performed in all patients with resectable esophageal cancer. Transthoracic-Laparoscopic Esophagectomy (TLE) is a minimally invasive method and considered to be the most appropriate method. In this study, we aim to evaluate and compare the perioperative outcome, and 1-year overall survival of TLE and Transhiatal Esophagectomy (THE) approaches. Methods: In this retrospective study, we reviewed the medical records of 108 patients with esophageal cancer undergoing TLE (n=44) or THE (n=64) between 2015 and 2018. The patients were followed for one year. The intraoperative and postoperative findings, as well as 1-year overall-survival, were compared between the two groups. Results: TLE compared to THE had a longer surgery duration (278.63±33.28 vs 223.28±33.99 min, P=0.001), a higher number of dissected lymph nodes (15.06±2.95 vs 10.21±2.58, P=0.001), less blood loss (345.45±178.76 vs 585.15±294.75 mL, P<0.001), and need for transfusion (20.5% vs 45.3%, P=0.006) during surgery as well as lower ICU stay (2.59±0.77 vs 3.90±0.83 days, P<0.001) and ward stay (8.77±0.96 vs 11.42±1.71 days, P<0.001). THE had somewhat higher complication than TLE, but with no significant differences. Conclusion: TLE had a similar rate of complication to THE approach, but with lower blood loss and lower ICU and hospital stay, it is a more appropriate method for esophagectomy.

Successful treatment of esophageal cancer with transhiatal esophagectomy after heart transplantation

2004 ◽  
Vol 78 (2) ◽  
pp. 702-705 ◽  
Author(s):  
Dipin Gupta ◽  
Mahender Macha ◽  
Valentino Piacentino ◽  
Arun K Singhal ◽  
Harvey F Sasken ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Heart Transplantation ◽  
Successful Treatment ◽  
Transhiatal Esophagectomy

Enteral Access is not Required for Esophageal Cancer Patients Undergoing Neoadjuvant Therapy

2016 ◽  
Vol 102 (3) ◽  
pp. 948-954 ◽  
Author(s):  
Mary E. Huerter ◽  
Eric J. Charles ◽  
Emily A. Downs ◽  
Yinin Hu ◽  
Christine L. Lau ◽  
...  
Keyword(s):  
Esophageal Cancer ◽  
Neoadjuvant Therapy ◽  
Cancer Patients ◽  
Enteral Access
Sign in / Sign up

Export Citation Format

Share Document